Literature DB >> 16443494

Positron emission tomography diagnosis of Alzheimer's disease.

R Edward Coleman1.   

Abstract

Positron emission tomography (PET) imaging of [18F]-2-fluoro-2-deoxy-D-glucose (FDG) is accurate in the early detection of Alzheimer's disease (AD) and in the differentiation of AD from the other causes of dementia. FDG-PET imaging is available widely and performed easily. Different patterns of abnormality with the various causes of dementia are well described. Semiquantitative methods of image interpretation are available. Medicare covers FDG-PET imaging for the narrow indication of differentiation of possible AD from frontotemporal dementia.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16443494     DOI： 10.1016/j.nic.2005.09.007

Source DB:  PubMed          Journal:  Neuroimaging Clin N Am        ISSN： 1052-5149            Impact factor:   2.264


  15 in total

Review 1.  The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias.

Authors:  Victor L Villemagne; Michelle T Fodero-Tavoletti; Kerryn E Pike; Roberto Cappai; Colin L Masters; Christopher C Rowe
Journal:  Mol Neurobiol       Date:  2008-08-09       Impact factor: 5.590

2.  Effect of hyperglycemia on brain and liver 18F-FDG standardized uptake value (FDG SUV) measured by quantitative positron emission tomography (PET) imaging.

Authors:  Benjamin L Viglianti; Ka Kit Wong; Stephanie M Wimer; Aishwarya Parameswaran; Bin Nan; Christy Ky; Danyelle M Townsend; Domenico Rubello; Kirk A Frey; Milton D Gross
Journal:  Biomed Pharmacother       Date:  2017-02-07       Impact factor: 6.529

3.  Mild Alzheimer's disease: a "position paper".

Authors:  J Delrieu; T Voisin; S Andrieu; S Belliard; J Belmin; F Blanchard; M Ceccaldi; J F Dartigues; B Defontaines; S Lehericy; C Mekies; O Moreaud; L Naccache; F Nourhashemi; P J Ousset; F Pasquier; P Payoux; F Puisieux; P Robert; J Touchon; B Vellas; B Dubois
Journal:  J Nutr Health Aging       Date:  2009-06       Impact factor: 4.075

Review 4.  Imaging biomarkers associated with cognitive decline: a review.

Authors:  Jonathan McConathy; Yvette I Sheline
Journal:  Biol Psychiatry       Date:  2014-09-16       Impact factor: 13.382

5.  Altered medial temporal lobe responses during visuospatial encoding in healthy APOE*4 carriers.

Authors:  Paul R Borghesani; L Clark Johnson; Amy L Shelton; Elaine R Peskind; Elizabeth H Aylward; Gerard D Schellenberg; Monique M Cherrier
Journal:  Neurobiol Aging       Date:  2007-03-09       Impact factor: 4.673

6.  Combining cognitive screening tests for the evaluation of mild cognitive impairment in the elderly.

Authors:  Rodolfo B Ladeira; Breno S Diniz; Paula V Nunes; Orestes V Forlenza
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

Review 7.  Neuropathology for the neuroradiologist: plaques and tangles.

Authors:  F J Wippold; N Cairns; K Vo; D M Holtzman; J C Morris
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-09       Impact factor: 3.825

8.  Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: an FDG PET study.

Authors:  Angelo Del Sole; Francesca Clerici; Arturo Chiti; Michela Lecchi; Claudio Mariani; Laura Maggiore; Lisa Mosconi; Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-17       Impact factor: 9.236

9.  MEG biomarker of Alzheimer's disease: Absence of a prefrontal generator during auditory sensory gating.

Authors:  Sanja Josef Golubic; Cheryl J Aine; Julia M Stephen; John C Adair; Janice E Knoefel; Selma Supek
Journal:  Hum Brain Mapp       Date:  2017-07-17       Impact factor: 5.038

10.  In vivo synaptic density relates to glucose metabolism at rest in healthy subjects, but is strongly modulated by regional differences.

Authors:  June van Aalst; Jenny Ceccarini; Stefan Sunaert; Patrick Dupont; Michel Koole; Koen Van Laere
Journal:  J Cereb Blood Flow Metab       Date:  2021-01-14       Impact factor: 6.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.